Access the full text.
Sign up today, get DeepDyve free for 14 days.
M. Lindheimer, J. Umans (2006)
Explaining and predicting preeclampsia.The New England journal of medicine, 355 10
I. Álvarez-Fernández, B. Prieto, Verónica Rodríguez, Y. Ruano, Ana Escudero, F. Álvarez (2014)
New biomarkers in diagnosis of early onset preeclampsia and imminent delivery prognosisClinical Chemistry and Laboratory Medicine (CCLM), 52
T. Reimer, H. Rohrmann, J. Stubert, U. Pecks, M. Glocker, D. Richter, B. Gerber (2013)
Angiogenic factors and acute-phase proteins in serum samples of preeclampsia and HELLP patients: a matched-pair analysisThe Journal of Maternal-Fetal & Neonatal Medicine, 26
S. Verlohren, I. Herraiz, O. Lapaire, D. Schlembach, H. Zeisler, P. Calda, J. Sabria, F. Markfeld-Erol, A. Galindo, K. Schoofs, B. Denk, H. Stepan (2014)
New Gestational Phase–Specific Cutoff Values for the Use of the Soluble fms-Like Tyrosine Kinase-1/Placental Growth Factor Ratio as a Diagnostic Test for PreeclampsiaHypertension, 63
Microarray profiling reveals that
W. Schaarschmidt, S. Rana, H. Stepan (2013)
The course of angiogenic factors in early- vs. late-onset preeclampsia and HELLP syndrome, 41
R. Thadhani, H. Hagmann, W. Schaarschmidt, B. Roth, T. Cingoez, S. Karumanchi, J. Wenger, Kathryn Lucchesi, Hector Tamez, T. Lindner, A. Fridman, U. Thome, A. Kribs, M. Danner, S. Hamacher, P. Mallmann, H. Stepan, T. Benzing (2016)
Removal of Soluble Fms-Like Tyrosine Kinase-1 by Dextran Sulfate Apheresis in Preeclampsia.Journal of the American Society of Nephrology : JASN, 27 3
T. Várkonyi, B. Nagy, T. Füle, A. Tarca, Katalin Karászi, Julianna Schonleber, P. Hupuczi, N. Mihalik, I. Kovalszky, J. Rigó, H. Meiri, Z. Papp, R. Romero, N. Than (2011)
Microarray profiling reveals that placental transcriptomes of early-onset HELLP syndrome and preeclampsia are similar.Placenta, 32 Suppl
Obst Gynecol, 103
S. Rana, Camille Powe, S. Salahuddin, S. Verlohren, F. Perschel, Richard Levine, K. Lim, Julia Wenger, R. Thadhani, S. Karumanchi (2012)
Angiogenic Factors and the Risk of Adverse Outcomes in Women With Suspected PreeclampsiaCirculation, 125
B. Sibai (2004)
HIGH-RISK PREGNANCY SERIES: AN EXPERT’S VIEW Diagnosis, Controversies, and Management of the Syndrome of Hemolysis, Elevated Liver Enzymes, and Low Platelet Count
S. Sep, J. Verbeek, G. Koek, L. Smits, M. Spaanderman, L. Peeters (2010)
Clinical differences between early-onset HELLP syndrome and early-onset preeclampsia during pregnancy and at least 6 months postpartum.American journal of obstetrics and gynecology, 202 3
B. Young, Richard Levine, S. Salahuddin, Cong Qian, K. Lim, S. Karumanchi, S. Rana (2010)
The use of angiogenic biomarkers to differentiate non-HELLP related thrombocytopenia from HELLP syndromeThe Journal of Maternal-Fetal & Neonatal Medicine, 23
Clin Chem Lab Med 2016; 54(7): e187e189 Letter to the Editor Covadonga Quirós, Francisco Suárez, Belén Prieto, Verónica Rodriguez, Óscar Vaquerizo and Francisco V. Álvarez Menéndez* DOI 10.1515/cclm-2015-0890 Received September 12, 2015; accepted October 15, 2015; previously published online November 18, 2015 Keywords: HELLP syndrome; PlGF; preeclampsia; sFlt-1; thrombocytopenia. To the Editor, The diagnosis of HELLP syndrome requires the presence of hemolysis (elevated unconjugated bilirubin, low serum haptoglobin or elevated lactate dehydrogenase concentrations) in association with significant increased liver enzymes and a platelet count below 100,000/mm3 , after ruling out other causes of hemolysis and thrombocytopenia [1, 2]. Deciding whether HELLP syndrome is a severe form of preeclampsia (PE) or not, is controversial [3]. The majority of patients with HELLP syndrome develop PE; however, approximately 10%20% of them do not show any signs of hypertension and/or proteinuria. Moreover, laboratory findings in HELLP syndrome usually do not correlate with the severity of hypertension or proteinuria. PE typically develops gradually while the onset of HELLP syndrome is frequently rapid [1, 2, 4]. There are women who attend the emergency department for a preeclampsia evaluation with low platelet count secondary to either gestational thrombocytopenia or immune thrombocytopenic purpura (ITP) or manifest
Clinical Chemistry and Laboratory Medicine (CCLM) – de Gruyter
Published: Jul 1, 2016
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.